CAC
TNGX icon

Cowen and Company’s Tango Therapeutics TNGX Stock Holding History

Cowen and Company’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$99K – 717
2023
Q4 		$99K Buy
+10,000
New +$86.8K 0.01% 243

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Cowen and Company's TNGX Position: Q1 2024 in Review

Cowen and Company sold out of Tango Therapeutics (TNGX) in Q1 2024, closing a stake of 10,000 shares — an estimated $99K sold.

Cowen and Company first reported a position in TNGX in Q4 2023 and held it in 1 quarter. The position peaked at $99K in Q4 2023. 126 funds tracked by Wall St. Rank hold TNGX as of Q1 2024.

  • Cowen and Company reported no remaining Tango Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 10,000 Tango Therapeutics shares in Q1 2024, an estimated $99K.
  • Cowen and Company first reported a position in Tango Therapeutics in Q4 2023 and held it in 1 quarter.
  • Cowen and Company's Tango Therapeutics position peaked at $99K in Q4 2023.
  • 126 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.